首页> 外文期刊>Journal of Crohn’s & colitis >Mesenchymal Stem Cell Injections for the Treatment of Perianal Crohn's Disease: What We Have Accomplished and What We Still Need to Do
【24h】

Mesenchymal Stem Cell Injections for the Treatment of Perianal Crohn's Disease: What We Have Accomplished and What We Still Need to Do

机译:间充质干细胞注射治疗肛门克罗恩病:我们所取得的成就以及我们仍然需要做的事情

获取原文
获取原文并翻译 | 示例
       

摘要

Perianal Crohn's disease [CD] is found in a quarter of patients with CD and remains notoriously difficult to treat. Several medical and surgical therapies are available. However, none is particularly effective nor reliably provides sustained remission. In addition, surgical intervention is complicated by poor healing and the potential for incontinence. Mesenchymal stem cell-based therapies provide a promising treatment alternative for perianal CD, with demonstrated safety, improved efficacy, and a decreased side effect profile. Several phase I, II, and now III randomised controlled trials have now reported safety and efficacy in treating perianal CD. The aim of this review is to discusses the outcomes of conventional treatment approaches, outcomes of mesenchymal stem cell therapies, considerations specific to stem cell-based therapies, and future directions for research.
机译:肛周克罗恩病[CD]在四分之一的CD患者中被发现,并且仍然难以治疗。有几种医学和外科治疗方法可供选择。然而,没有一种疗法特别有效,也不能可靠地提供持续缓解。此外,手术治疗因愈合不良和可能出现尿失禁而变得复杂。以间充质干细胞为基础的疗法为肛周CD提供了一种有希望的治疗选择,具有安全性、改善疗效和减少副作用的特点。一些I期、II期和现在的III期随机对照试验已经报道了治疗肛周CD的安全性和有效性。本综述的目的是讨论常规治疗方法的结果、间充质干细胞治疗的结果、基于干细胞的治疗的特殊考虑以及未来的研究方向。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号